Clinical Vaccination Guidance for Pregnant People

Registration is not required.

Date: Thursday, August 10, 2023

Time: 2:00 PM – 3:00 PM ET 

A few minutes before the webinar begins, please click the link below to join:

https://www.zoomgov.com/j/1604412918

Webinar ID: 160 441 2918

Passcode: 650748

Telephone:
Dial (for higher quality, dial a number based on your current location):
+1 669 254 5252 US (San Jose)
+1 646 828 7666 US (New York)
+1 646 964 1167 US (US Spanish Line)
+1 415 449 4000 US (US Spanish Line)
+1 551 285 1373 US
+1 669 216 1590 US (San Jose)

One-tap mobile:
+16692545252,,1604412918#,,,,*650748# US (San Jose)
+16468287666,,1604412918#,,,,*650748# US (New York)

International Numbers

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC’s role in the topic covered during the presentation.
3. Describe the topic’s implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-specific Objectives

1. Discuss current CDC and ACOG recommendations for vaccination during pregnancy, with a focus on Tdap, influenza, and COVID-19 vaccines.
2. Cite the current vaccination coverage for Tdap, influenza, and COVID-19 among pregnant people in the United States.
3. Explain the burden of pertussis, influenza virus, and SARS-CoV-2 infections in pregnant people and infants.
4. Describe the benefits of Tdap, influenza, and COVID-19 vaccination during pregnancy for both pregnant people and their infants.
5. Review clinical considerations and best practices for making strong recommendations for vaccination and overcoming barriers to vaccination among pregnant people.

• Pregnancy and Whooping Cough
• Influenza and Pregnancy
• Influenza Vaccine and Pregnancy
• COVID-19 in Infants ages 0-5 months
• Vaccination Coverage during Pregnancy
• Vaccine Safety Publications

To receive continuing education (CE) for WD4520-081023 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Clinical Vaccination Guidance for Pregnant People, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520-081023. Follow the steps below by September 12, 2025.

1. Register for and complete the course.
2. Pass the post-assessment at 75%.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation. 

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours. 

CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-23-058-L04-P and enduring JA4008229-0000-23-059-H04-P.

Once credit is claimed, an unofficial statement of credit is immediately available on CDC TRAIN. Official credit will be uploaded within 60 days on the NABP/CPE Monitor. 

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program. 

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614. 

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession. 

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients with the exception of Dr. Naima Joseph who would like to disclose that she is a co-investigator on a Paxlovid in pregnancy study for Pfizer. All of the relevant financial relationships listed for these individuals have been mitigated.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Fees: No fees are charged for CDC’s CE activities.

• Physicians
• Nurses
• Pharmacists
• Veterinarians
• Physician Assistants
• Health Educators
• Other Clinicians

System requirements to use Zoomexternal icon

• Contact Information:coca@cdc.gov
• Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
• Method of Participation:You may participate in the educational activity by viewing the program information above.